Claims of the Application:

1-17. (Canceled)

18. (Previously presented) A pharmaceutical composition comprising:

a) a tablet layer comprising an antihistaminic drug, a cellulose derivative, a polyol, a starch derivative, and a disintegrant; and

b) a tablet layer comprising a decongestant drug and a sustained release compound.

19. (Previously presented) The pharmaceutical composition of claim 18, wherein an antihistaminic drug comprises crystalline Form X of fexofenadine hydrochloride.

20. (Previously presented) The pharmaceutical composition of claim 18, wherein a cellulose derivative comprises powdered cellulose, microcrystalline cellulose, or a mixture thereof.

21. (Previously presented) The pharmaceutical composition of claim 18, wherein a polyol comprises mannitol, xylitol, or a mixture thereof.

22. (Previously presented) The pharmaceutical composition of claim 18, wherein a starch derivative comprises corn starch, potato starch, starch 155, or a mixture of any two or more thereof.

23. (Previously presented) The pharmaceutical composition of claim 18, wherein a disintegrant comprises sodium starch glycolate, sodium carboxymethylcellulose, crosslinked polyvinylpyrrolidone, croscarmellose sodium, or a mixture of any two or more thereof.

24. (Previously presented) The pharmaceutical composition of claim 18, wherein a decongestant drug comprises pseudoephedrine, phenylephrine,

phenylpropanolamine, a pharmaceutically acceptable salt of any of the foregoing, or a mixture of any two or more thereof.

25. (Previously presented) The pharmaceutical composition of claim 18, wherein a sustained release compound comprises: a mixture comprising polyvinyl acetate and povidone; sodium alginate; xanthan gum; carbopol; chitosan; ethyl cellulose; a cellulose ether; a methacrylic polymer; or a mixture of any two or more thereof.

26. (Previously presented) The pharmaceutical composition of claim 18, wherein an antihistaminic drug comprises crystalline form X of fexofenadine hydrochloride and a decongestant drug comprises pseudoephedrine or a salt thereof.

27. (Previously presented) A pharmaceutical composition comprising:

a) a tablet layer comprising an antihistaminic drug, cellulose, mannitol, starch, and croscarmellose sodium; and

b) a tablet layer comprising a decongestant drug and a mixture of polyvinyl acetate and povidone.

28. (Previously presented) The pharmaceutical composition of claim 27, wherein an antihistaminic drug comprises crystalline form X of fexofenadine hydrochloride.

29. (Previously presented) The pharmaceutical composition of claim 27, wherein a decongestant drug comprises a salt of pseudoephedrine.

30. (Previously presented) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 20 to about 45 percent by weight cellulose.

31. (Previously presented) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 10 to about 30 percent by weight mannitol.

32. (Previously presented) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 5 to about 25 percent by weight starch.

33. (Previously presented) The pharmaceutical composition of claim 27, wherein tablet layer a) comprises about 4 to about 15 percent by weight croscarmellose sodium.

34. (Previously presented) The pharmaceutical composition of claim 27, wherein tablet layer b) comprises about 40 to about 80 percent by weight of a mixture of polyvinyl acetate and povidone.

35. (Previously presented) The pharmaceutical composition of claim 27, wherein tablet layer b) comprises about 40 to about 80 percent by weight of a mixture comprising about 80 percent polyvinyl acetate and about 19 percent povidone.

36. (Previously presented) The pharmaceutical composition of claim 27, wherein tablet layer b) is formed by compressing granules comprising a decongestant drug and a mixture of polyvinyl acetate and povidone, about 5-15 percent of the granules being retained on an 80 mesh sieve, about 10-25 percent of the granules being retained on a 100 mesh sieve, and about 80-95 percent of the granules being retained on a 200 mesh sieve.

37. (Currently amended) A pharmaceutical composition comprising:

a) a tablet layer comprising crystalline form X of fexofenadine hydrochloride, about 20 to about 45 percent by weight cellulose, about 10 to about 30 percent by weight mannitol, about 5 to about 25 percent by weight starch, and about ~~5~~ 4 to about ~~25~~ 15 percent by weight ~~starch~~ of a disintegrant; and

b) a tablet layer comprising a salt of pseudoephedrine and about 40 to about 80 percent by weight of a mixture comprising about 80 percent polyvinyl acetate and about 19 percent povidone.